TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A gastroenterology research roundup published Nov. 5 reports that gallbladder and biliary diseases affected more than 264 million people worldwide in 2023 and contributed to over 146,000 deaths. It also highlights research questions about low-dose amitriptyline for IBS and a Polish study linking rectal polyps to greater cancer and recurrence risks after removal.
A gastroenterology research roundup published Nov. 5 reports that gallbladder and biliary diseases affected more than 264 million people worldwide in 2023 and contributed to over 146,000 deaths. The MedPage Today report also flags research on low-dose amitriptyline for irritable bowel syndrome (IBS) and a study associating rectal location of large colorectal polyps with greater odds of invasive cancer and recurrence after endoscopic removal.
The global estimates concern diseases including gallstones, cholecystitis and cholangitis, according to the roundup, which cites research in The Lancet Gastroenterology & Hepatology. The figures describe the worldwide burden in 2023; the supplied report does not provide a country-by-country breakdown or a comparison with earlier years.
For IBS, the roundup points to a study in Clinical Gastroenterology and Hepatology asking whether gastrointestinal and psychological symptom profiles can predict response to low-dose amitriptyline. The source describes this as a research question, not a confirmed treatment rule or a reported result. It does not give the study’s sample size, findings or recommended prescribing approach.
A retrospective cohort study from Poland, published in Gut, found that among patients who had endoscopic mucosal resection of large colorectal polyps, rectal lesions were linked with a higher likelihood of invasive cancer and recurrence than lesions in the colon. The roundup does not report absolute risks or establish that rectal location itself caused either outcome.
Disease Burden and Polyp Risk
The 2023 figures put the worldwide burden of gallbladder and biliary conditions in perspective: the report describes more than 264 million affected people and over 146,000 deaths in a single year. Those totals point to a substantial global health issue, although the roundup alone cannot explain which diseases, regions or factors account for most of the burden.
The polyp study may matter to clinicians assessing patients after removal of large lesions because it suggests rectal location could be associated with different risks from colonic location. However, a retrospective association does not by itself establish an individual patient’s prognosis or show that follow-up guidance should change. The IBS item is also relevant to care, but the source provides a question under investigation rather than evidence that symptom profiles can reliably guide amitriptyline use.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Three Findings in a Research Roundup
The items appeared in a broader MedPage Today gastroenterology and hepatology roundup by managing editor Ian Ingram, dated Nov. 5, 2026. It grouped newly reported research and professional developments across digestive and liver health rather than presenting one linked study or a unified clinical guideline.
Other items in the roundup included a case study of gene correction in a 66-year-old man with severe alpha-1 antitrypsin deficiency, consensus definitions for acute-on-chronic liver failure, and a U.S. inspector general finding that fewer than one in four Medicaid beneficiaries with hepatitis C received treatment within six months of testing. These are separate developments and do not directly establish conclusions about the gallbladder, IBS or polyp studies.
“Can certain gastrointestinal and psychological symptom profiles in irritable bowel syndrome predict response to low-dose amitriptyline?”
— MedPage Today roundup, describing the Clinical Gastroenterology and Hepatology study
Study Details Still Missing
The source roundup does not supply the methods behind the global disease estimates, how deaths were attributed, or how the 2023 totals compare with other years. It also gives no absolute cancer or recurrence rates for the rectal-polyp cohort, details about its size, or information that would show whether the association persists after accounting for other patient and lesion characteristics.
For the amitriptyline research, the reported question does not establish that symptom profiles predict treatment response. The roundup provides no outcome data, dosage details beyond “low-dose,” or safety findings. Readers should not treat the brief summaries as individual medical guidance; treatment and surveillance decisions require discussion with a qualified health professional.
Awaiting Full Study Results
The next useful details will come from the full publications: the methods and geographic patterns behind the global estimates, the IBS study’s results on symptom profiles and response, and the Polish cohort’s absolute risks and limitations. The source does not announce a specific release date or follow-up milestone for these studies.
Until those details are available, the reported findings are best read at their stated level: global estimates for 2023, an unanswered question about amitriptyline response, and a retrospective association between rectal lesion location and outcomes after resection. Any changes to clinical practice would require evidence and guidance beyond the summaries provided here.
Key Questions
How many people had gallbladder or biliary disease in 2023?
The roundup reports more than 264 million people worldwide had gallbladder and biliary diseases in 2023. The conditions named include gallstones, cholecystitis and cholangitis.
How many deaths were linked to these diseases?
The diseases together contributed to over 146,000 deaths in 2023, according to the research cited by MedPage Today. The supplied report does not give regional totals or comparisons with prior years.
Does the roundup show that amitriptyline works for IBS?
No treatment result is provided. The roundup says a study examined whether gastrointestinal and psychological symptom profiles could predict response to low-dose amitriptyline, but it does not state the findings.
What did the large-polyp study find about rectal lesions?
A Polish retrospective cohort study linked rectal lesions removed through endoscopic mucosal resection with a higher likelihood of invasive cancer and recurrence than colonic lesions. The summary gives no absolute risk figures and does not establish causation.
Source: medpagetoday.com
